OOIR: Observatory of International Research

Papers

(The TQCC of Drug Resistance Updates is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance	264
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment	171
Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors	159
Taxanes in cancer treatment: Activity, chemoresistance and its overcoming	121
Anticancer drug resistance: An update and perspective	121
The role of alternative splicing in cancer: From oncogenesis to drug resistance	116
FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy	108
Surmounting cancer drug resistance: New insights from the perspective of N6-methyladenosine RNA modification	107
Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance	104
Therapeutic strategies to overcome taxane resistance in cancer	101
Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies	99
Novel nanomedicines to overcome cancer multidrug resistance	94
Hypoxia as a driver of resistance to immunotherapy	93
Long non-coding RNAs as a determinant of cancer drug resistance: Towards the overcoming of chemoresistance via modulation of lncRNAs	88
Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance	79
A review on antimicrobial botanicals, phytochemicals and natural resistance modifying agents from Apocynaceae family: Possible therapeutic approaches against multidrug resistance in pathogenic microor	78
Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses	77
Nanomedicine to target multidrug resistant tumors	71
Antimicrobial peptides for combating drug-resistant bacterial infections	67
Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function	60
Repurposing old drugs to fight multidrug resistant cancers	58
New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma	48
New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects	47
Metal- and metalloid-based compounds to target and reverse cancer multidrug resistance	45
GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer	44

Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer	43
COVID-19 update: The race to therapeutic development	43
Thirty years of VRE in Germany – “expect the unexpected”: The view from the National Reference Centre for Staphylococci and Enterococci	42
Impact of cancer metabolism on therapy resistance – Clinical implications	42
The key roles of the lysine acetyltransferases KAT6A and KAT6B in physiology and pathology	42
Overcoming cancer chemotherapy resistance by the induction of ferroptosis	41
Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine	40
Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs	38
Long non-coding RNA mediated drug resistance in breast cancer	38
Cross-resistance and drug sequence in prostate cancer	37
Targeting multidrug resistance-associated protein 1 (MRP1)-expressing cancers: Beyond pharmacological inhibition	37
Metallothionein isoforms as double agents – Their roles in carcinogenesis, cancer progression and chemoresistance	37
Emerging role of autophagy in anti-tumor immunity: Implications for the modulation of immunotherapy resistance	34
ABC transporters affects tumor immune microenvironment to regulate cancer immunotherapy and multidrug resistance	33
Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade	33
The Omicron variant of concern: Diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies	31
Current therapy and drug resistance in metastatic castration-resistant prostate cancer	31
Molecular Modeling Strategies of Cancer Multidrug Resistance	31
Selenium and tellurium in the development of novel small molecules and nanoparticles as cancer multidrug resistance reversal agents	31
In vitro biomimetic models for glioblastoma-a promising tool for drug response studies	29
Targeting metabolism to overcome cancer drug resistance: A promising therapeutic strategy for diffuse large B cell lymphoma	29
The role of extracellular vesicles in the transfer of drug resistance competences to cancer cells	28
N6-methyladenosine-modified circular RNA QSOX1 promotes colorectal cancer resistance to anti-CTLA-4 therapy through induction of intratumoral regulatory T cells	26
Exosomal circular RNAs: A chief culprit in cancer chemotherapy resistance	24
The strategic roles of four enzymes in the interconnection between metabolism and oncogene activation in non-small cell lung cancer: Therapeutic implications	23
Loss of cancer-associated fibroblast-derived exosomal DACT3-AS1 promotes malignant transformation and ferroptosis-mediated oxaliplatin resistance in gastric cancer	23
Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers	23
The role of endolysosomal trafficking in anticancer drug resistance	23